The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Sensyne Health Plc

11 Apr 2022 12:00

RNS Number : 9604H
Peel Hunt LLP
11 April 2022
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Sensyne Health Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Sensyne Health Plc

(d) Date dealing undertaken:

08 April 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Buy

17,343,328

 

3.38 GBx

1.25 GBx

Ordinary Shares

Sell

21,101,891

 

3.50 GBx

1.18 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

Date of disclosure:

11 April 2022

 

Contact name:

Alexandra Forner

Telephone number:

0207 847 4740

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERUASKRURUSARR
Date   Source Headline
3rd Nov 20213:00 pmBUSForm 8.3 - SENS LN
3rd Nov 20212:10 pmRNSForm 8.3 - Sensyne Health plc
3rd Nov 20211:54 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 20211:10 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 202112:58 pmGNWInvesco Ltd.: Form 8 (OPD) - Sensyne Health PLC
3rd Nov 202112:08 pmRNSHolding(s) in Company
3rd Nov 202112:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
3rd Nov 20219:51 amRNSForm 8.5 (EPT/RI)
3rd Nov 20218:23 amRNSForm 8.3 - Sensyne Health Plc
2nd Nov 20213:02 pmGNWForm 8.3 - Octopus Investments - Sensyne Health plc
2nd Nov 20217:00 amRNSStrategic update, FSP triggered by potential MBO
29th Oct 20215:04 pmRNSResults of Annual General Meeting
21st Oct 20217:00 amRNSMagnifEye European regulatory certification
15th Oct 20217:00 amRNSSensyne and OMNY Health Sign Teaming Agreement
6th Oct 20217:00 amRNSHoldings in Company
6th Oct 20217:00 amRNSAnnual Report and Accounts
4th Oct 20212:05 pmRNSSecond Price Monitoring Extn
4th Oct 20212:00 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSSensyne Health 2021 Financial Results
24th Sep 20217:00 amRNSNotice of Preliminary Results
9th Sep 20217:00 amRNSLaunch of SENSIGHT data analytics platform
2nd Sep 20217:00 amRNSSensyne & GOSH partner in child disease research
19th Aug 20217:00 amRNSSensyne SRA With Sentara Healthcare
10th Aug 20217:00 amRNSSensyne announces AI drug discovery project
2nd Aug 20217:01 amRNSBoard Change
2nd Aug 20217:00 amRNSSensyne dataset reaches 60m patients
22nd Jul 20217:00 amRNSAppointment of Chief Scientific Officer
19th Jul 20217:00 amRNSSensyne Health Provides Strategic Update
18th Jun 20217:00 amRNSNED Appointment
17th Jun 20213:02 pmRNSHolding(s) in Company
1st Jun 20217:00 amRNSMagnifEye Production Contract with UK DHSC
28th May 20212:24 pmRNSShare Option Award
27th May 20217:00 amRNSTrading Update
25th May 20211:13 pmRNSHolding(s) in Company
24th May 20217:00 amRNSSRA with Colorado Center for Personalized Medicine
21st May 20219:14 amRNSPharmaceutical collaboration
21st May 20217:00 amRNSSensyne signs SRA with St. Luke’s
7th May 202111:12 amRNSHolding(s) in Company
7th May 20217:00 amRNSMagnifEye Gains MHRA Approval
6th May 20217:00 amRNSValue Creation Plan Award
30th Apr 20217:00 amRNSSensyne SRA with Royal Devon and Exeter NHS Trust
16th Apr 20217:00 amRNSIssue of Shares and Total Voting Rights
12th Mar 20217:00 amRNSAgreement with the UK DHSC
1st Mar 20217:00 amRNSSYNE-COV Achieves UK Regulatory Approval
1st Mar 20217:00 amRNSBoard Changes
10th Feb 20212:06 pmRNSSecond Price Monitoring Extn
10th Feb 20212:00 pmRNSPrice Monitoring Extension
9th Feb 20217:48 amRNSSensyne licenses MagnifEye technology to Excalibur
5th Feb 20212:57 pmRNSHoldings in Company
5th Feb 20212:24 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.